Highlights Atara Biotherapeutics, Inc.

Equities

ATRA

US0465131078

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-17 pm EDT			5-day change	1st Jan Change
0.61 ^USD	+1.06%		+15.12%	+18.95%

May. 09	Earnings Flash (ATRA) ATARA BIOTHERAPEUTICS Reports Q1 Revenue $27.4M	MT
Apr. 01	Stifel Adjusts Atara Biotherapeutics Price Target to $2.30 From $4.80, Maintains Hold Rating	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Earnings Flash (ATRA) ATARA BIOTHERAPEUTICS Reports Q1 Revenue $27.4M	May. 09	MT
Atara Biotherapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28	CI
Earnings Flash (ATRA) ATARA BIOTHERAPEUTICS Reports Q4 Revenue $4.3M	Mar. 28	MT
Atara Biotherapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Mar. 28	CI
North American Morning Briefing : Stock Futures -2-	Mar. 13	DJ
Atara Biotherapeutics Gets FDA Clearance for ATA3219 IND Application	Feb. 29	DJ
Atara Biotherapeutics Submits New Drug Application to FDA for ATA3219 to Treat Lupus Nephritis	Feb. 14	MT
Atara Biotherapeutics, Inc. Announces Submission of Investigational New Drug Application for ATA3219 for Treatment of Lupus Nephritis	Feb. 14	CI
Atara Biotherapeutics, Inc. and Pierre Fabre Laboratories Announce Publication of Phase 3 ALLELE Tab-cel®? Data in The Lancet Oncology	Jan. 31	CI
Atara Biotherapeutics, Inc. Announces Closing of Expanded Global Tab-Cel Partnership with Pierre Fabre Laboratories	Dec. 20	CI
Atara Biotherapeutics, Inc. Presents Positive Preclinical Data on ATA3431, A Next-Generation Allogeneic CD20/CD19-Targeted CAR, at the 65th ASH Annual Meeting	Dec. 11	CI
Atara Biotherapeutics, Inc. Announces Primary Analysis Data from Phase 2 EMBOLD Clinical Trial of ATA188 in Non-Active Progressive Multiple Sclerosis	Nov. 08	CI
Earnings Flash (ATRA) ATARA BIOTHERAPEUTICS Reports Q3 Revenue $2.1M	Nov. 01	MT
Atara Biotherapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 01	CI
Atara Biotherapeutics, Inc. Announces Expanded Global Tab-Cel Partnership with Pierre Fabre Laboratories	Nov. 01	CI
Atara Plans to File Biologics License Application for Tabelecleucel in Q2 of 2024	23-09-19	MT
Atara Biotherapeutics to Submit New FDA Biologics License Application in 2Q	23-09-19	DJ
Atara Biotherapeutics, Inc. Announces Plans to Submit Tab-cel® BLA in Second Quarter 2024 Following FDA Agreement on Comparability	23-09-19	CI
Earnings Flash (ATRA) ATARA BIOTHERAPEUTICS Reports Q2 Revenue $957,000, vs. Street Est of $3.8M	23-08-08	MT
Atara Biotherapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-08	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Atara Biotherapeutics, Inc.

Equities

ATRA

US0465131078

Highlights

Filters